Search results for " Transjugular Intrahepatic"

showing 4 items of 14 documents

TIPS for Prevention of Recurrent Bleeding in Patients with Cirrhosis: Meta-analysis of Randomized Clinical Trials

1999

To compare the effects of transjugular intrahepatic portosystemic shunt (TIPS) creation with those of endoscopic treatment with or without propranolol administration (i.e, conventional treatment) on recurrent bleeding, encephalopathy, and mortality by using meta-analysis of 11 published randomized clinical trials.Data from 11 relevant studies were retrieved by means of computerized and manual search. The combinability of the studies was assessed in terms of clinical and statistical criteria. Data were extracted on the basis of the intention-to-treat principle, and treatment effects were measured as risk differences between TIPS creation and conventional treatment. Pooled estimates were comp…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentEncephalopathyEsophageal and Gastric Variceslaw.inventionRandomized controlled trialRecurrenceRisk FactorslawSclerotherapymedicineSclerotherapyHumansRadiology Nuclear Medicine and imagingbusiness.industryLiver DiseasesHemostasis EndoscopicMiddle Agedmedicine.diseaseSurgeryHepatic EncephalopathyMeta-analysisPortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticGastrointestinal HemorrhageVaricesbusinessTransjugular intrahepatic portosystemic shuntRadiology
researchProduct

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data

2007

Several randomized controlled trials have compared a transjugular intrahepatic portosystemic shunt (TIPS) with large-volume paracentesis in cirrhotic patients with refractory ascites. Although all agree that TIPS reduces the recurrence rate of ascites, survival is controversial. The aim of this study was to compare the effects of TIPS and large-volume paracentesis in cirrhotic patients with refractory ascites by means of meta-analysis of individual patient data from 4 randomized controlled trials.The study population consisted of 305 patients: 149 allocated to TIPS and 156 to paracentesis. Cumulative probabilities of transplant-free survival and of hepatic encephalopathy (HE) were estimated…

Liver CirrhosisMalemedicine.medical_specialtymedicine.medical_treatmentKaplan-Meier EstimateGastroenterologySpontaneous bacterial peritonitisModel for End-Stage Liver DiseaseHepatorenal syndromeRisk FactorsInternal medicineAscitesmedicineParacentesisHumansParacentesisHepatic encephalopathyAgedFirst episodeHepatologymedicine.diagnostic_testbusiness.industrySodiumGastroenterologyAscitesBilirubinPatient dataMiddle Agedmedicine.diseaseLiver TransplantationSurgeryTreatment OutcomeMeta-analysisHepatic EncephalopathyRegression AnalysisFemaleRefractory ascitesPortasystemic Shunt Transjugular Intrahepaticmedicine.symptombusinessTransjugular intrahepatic portosystemic shuntGastroenterology
researchProduct

Reply to: “Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?”

2021

Liver Cirrhosismedicine.medical_specialtyCirrhosisIndex (economics)Hepatologybusiness.industryPrognosismedicine.diseasePrognostic scoreText miningInternal medicinemedicineHumansIn patientPortasystemic Shunt Transjugular IntrahepaticbusinessJournal of Hepatology
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct